RANI THERAPEUTICS HOLDINGS-A (RANI) Stock Price, Forecast & Analysis
NASDAQ:RANI • US7530181004
RANI Key Statistics, Chart & Performance
The current stock price of RANI is 1.37 USD. In the past month the price increased by 7.03%. In the past year, price decreased by -10.46%.
RANI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to RANI. When comparing the yearly performance of all stocks, RANI is a bad performer in the overall market: 80.01% of all stocks are doing better.
RANI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RANI. RANI has a bad profitability rating. Also its financial health evaluation is rather negative.
RANI Financial Highlights
Over the last trailing twelve months RANI reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 25.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -279.27% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RANI Forecast & Estimates
9 analysts have analysed RANI and the average price target is 9.44 USD. This implies a price increase of 588.69% is expected in the next year compared to the current price of 1.37.
RANI Ownership
RANI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.34 | 994.53B | ||
| JNJ | JOHNSON & JOHNSON | 21.32 | 598.542B | ||
| MRK | MERCK & CO. INC. | 22.88 | 307.324B | ||
| PFE | PFIZER INC | 9.21 | 157.21B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.25 | 126.97B | ||
| ZTS | ZOETIS INC | 19.09 | 57.775B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.91 | 26.674B | ||
| VTRS | VIATRIS INC | 5.9 | 17.196B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.25 | 13.117B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.12 | 8.262B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RANI
Company Profile
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Company Info
RANI THERAPEUTICS HOLDINGS-A
2051 Ringwood Avenue
San Jose CALIFORNIA US
CEO: Talat Imran
Employees: 105
Phone: 14084573700
RANI THERAPEUTICS HOLDINGS-A / RANI FAQ
Can you describe the business of RANI THERAPEUTICS HOLDINGS-A?
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
What is the stock price of RANI THERAPEUTICS HOLDINGS-A today?
The current stock price of RANI is 1.37 USD. The price decreased by -0.72% in the last trading session.
What is the dividend status of RANI THERAPEUTICS HOLDINGS-A?
RANI does not pay a dividend.
How is the ChartMill rating for RANI THERAPEUTICS HOLDINGS-A?
RANI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is RANI THERAPEUTICS HOLDINGS-A (RANI) stock traded?
RANI stock is listed on the Nasdaq exchange.
Can you provide the market cap for RANI THERAPEUTICS HOLDINGS-A?
RANI THERAPEUTICS HOLDINGS-A (RANI) has a market capitalization of 166.48M USD. This makes RANI a Micro Cap stock.
What is the outstanding short interest for RANI THERAPEUTICS HOLDINGS-A?
The outstanding short interest for RANI THERAPEUTICS HOLDINGS-A (RANI) is 14.08% of its float.